Fewer than one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it issues its initial recommendations on the medications.
Given more than one billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs.
According to projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a chronic disease that can be managed with thorough and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are significant hurdles to broad access to the jabs that can aid individuals in losing significant body mass, explains the body.
Skinny Jab Scarcity
Even in the current most optimistic scenario, the supply of these medications would only suffice for about 100 million people – less than 10% of those who need them, per the health organization.
The guideline encourages countries and companies to increase access, by approaches including voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so people reduce food intake.
Individuals commonly see weight reduction in the initial weeks of commencing the regular doses.
Studies suggests users may regain a significant portion after a year of stopping the treatment, as their normal food cravings come back.
To be above a healthy weight increases your likelihood for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts people in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
